<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8">
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@picocss/pico@2/css/pico.classless.min.css">
    <title>Report 06-Sep-2025</title>
</head>
<body>
<main>
<a href="https://github.com/pathikrit/zeitgeist" target="_blank" rel="noopener" style="float: right;">
    <img src="https://github.githubassets.com/images/modules/logos_page/GitHub-Mark.png" alt="GitHub" width="30" height="30">
</a>
<h1>Daily Memo (06-Sep-2025)</h1>
<h2>Key News Bullets</h2>
<ul>
<li><strong>Fed Policy &amp; US Economy:</strong> Second consecutive weak jobs report challenges the US economic narrative; Fed rate hikes and emergency cuts are seen as highly unlikely for 2025, with moderate expectation for multiple (2-3) rate cuts. Trump evaluating candidates for next Fed chair.</li>
<li><strong>Geopolitics:</strong> Venezuela engages in provocative military signaling against US ships, with mounting US military presence in the Caribbean. Israel orders mass evacuation in Gaza, raising the risk of further Middle East instability.</li>
<li><strong>US Domestic Policy:</strong> High likelihood of government shutdown remains; ongoing immigration enforcement actions, including a major raid at a Hyundai EV plant, testing US-South Korea relations.</li>
<li><strong>COVID Policy:</strong> Trump and RFK Jr. inject new uncertainty into public health/vaccine messaging; vaccine chaos in Medicare and the potential end of some federal vaccine mandates discussed.</li>
<li><strong>AI &amp; Tech:</strong> Apple event to focus on iPhones, not major AI upgrades to Siri. No major breakthroughs expected from startups in AI model leadership this year; OpenAI’s structure (potential for-profit conversion and management moves) remains in flux.</li>
<li><strong>Sector Specific:</strong> WHO adds GLP-1 drugs (Ozempic, Mounjaro) to its essential medicines list, underscoring the importance of diabetes/obesity treatments. SpaceX on track for another record commercial launch year, further cementing sector dominance.</li>
</ul>
<hr />
<h2>Macro &amp; Policy</h2>
<h3>Rates, Growth, and Credit</h3>
<ul>
<li><strong>Interest Rate Direction:</strong> The path remains toward moderate easing; further Fed rate hikes or drastic cuts are seen as highly unlikely. The market expects at least some rate cuts (most likely 2-3 in 2025), keeping longer duration yields capped and supporting both equities and credit.</li>
<li><strong>Growth:</strong> Recession risk in the US remains low but notable signs of fragility (weak jobs data) may add volatility, particularly if further economic metrics disappoint.</li>
<li><strong>Inflation:</strong> Odds of runaway inflation or Treasury default remain remote. Inflation expectations are anchored, keeping bond and TIPS risk moderate.</li>
<li><strong>Fiscal Uncertainty:</strong> A government shutdown is a near coin-flip risk for 2025; this raises short-term volatility, especially for sectors reliant on government contracts, and could trigger a temporary flight to safety if the event materializes.</li>
<li><strong>Second-Order Effects:</strong> US default risk remains low, but persistent political brinkmanship may incrementally raise Treasury term premiums.</li>
</ul>
<h2>Geopolitics &amp; Global</h2>
<h3>MENA &amp; Oil Risk</h3>
<ul>
<li><strong>Middle East:</strong> Israeli military operations and evacuation orders in Gaza combined with ongoing humanitarian issues keep regional instability elevated. Little progress expected on Israel-Saudi normalization, so no major downward pressure on oil or defense sector risk premiums.</li>
<li><strong>Venezuela:</strong> Increased US-Venezuela tension and erratic military posturing do not represent direct systemic market risks yet, but the region is a growing wild card for oil logistics and defense.</li>
<li><strong>Europe:</strong> French political turbulence confirmed with Bayrou's imminent exit as PM; effect on EU credit and FX markets is minimal, but adds to the general European volatility backdrop.</li>
</ul>
<h3>Asia</h3>
<ul>
<li><strong>South Korea:</strong> US-South Korea relations veer into tension with the Hyundai raid, introducing supply chain and trade policy risks for the auto/EV and tech manufacturing sectors. Potential for further incidents involving strategic industrial sites.</li>
</ul>
<h2>Sector &amp; Asset Class Considerations</h2>
<h3>Equities (Broad/Tech)</h3>
<ul>
<li><strong>Market Breadth:</strong> Soft landing consensus for US equities holds, but earnings growth will increasingly depend on policy clarity and AI/semis momentum.</li>
<li><strong>Market Leadership:</strong> Strong market expectation for Nvidia to end the year as the largest company (beating Apple and Alphabet), reinforcing current market rotation into semiconductors, AI hardware/software, and associated cloud/data infrastructure.</li>
<li><strong>Circuit Breaker Risk:</strong> While risk of a US marketwide circuit breaker event is seen as low, persistent volatility from policy and global shocks deserves monitoring, particularly with the contentious US political backdrop.</li>
</ul>
<h3>Tech Sector &amp; AI</h3>
<ul>
<li><strong>AI Frontier:</strong> Newcomer disruption in large AI models (from Meta, Mistral, DeepSeek, etc.) is not anticipated; status quo favors incumbents (OpenAI, Google), but OpenAI’s structure/management questions generate ongoing uncertainty.</li>
<li><strong>Big Tech Governance:</strong> No imminent CEO changes expected at Amazon, Apple, or Coinbase, reducing idiosyncratic risk for these firms. OpenAI leadership moves and possible for-profit pivot may stir long-term sector expectations.</li>
<li><strong>Fintech:</strong> High chance of “X Money” launch, suggesting ongoing payment innovation and potential disruption in social/commerce venues.</li>
</ul>
<h3>Healthcare</h3>
<ul>
<li><strong>Diabetes &amp; Obesity:</strong> The inclusion of GLP-1 drugs on the WHO essential medicines list signals enduring demand for diabetes/obesity therapeutics; long-term support for firms in this area as global access (and likely pricing power) rises.</li>
<li><strong>COVID Policy:</strong> Federal vaccine mandates may be eased, and vaccine access remains patchy for seniors, but no transformational new pandemic policy; health insurance and public health policy risk remain moderate.</li>
</ul>
<h3>Defense, Energy, Aerospace</h3>
<ul>
<li><strong>Defense:</strong> Elevated risk premium persists for defense-related industries due to Middle Eastern (Israel-Gaza) and South American (Venezuela) tensions.</li>
<li><strong>Aerospace:</strong> SpaceX set for another record commercial launch year, underscoring barriers to entry and consolidation of leadership in space launch and satellite deployment.</li>
<li><strong>Oil/Energy:</strong> No major de-escalation in OPEC/MENA politics; oil prices remain supported by insecurity premium rather than fresh diplomatic breakthroughs.</li>
</ul>
<h3>Crypto &amp; Alternatives</h3>
<ul>
<li><strong>Digital Assets:</strong> Crypto sector faces no immediate regulatory/tech disruption; bitcoin protocol upgrades unlikely in the near term. Coinbase and leading exchanges’ governance stable.</li>
<li><strong>Gold/Commodities:</strong> No acute new inflation or systemic risk triggers bump to commodity complex this week.</li>
</ul>
<h2>Individual Names &amp; Events</h2>
<ul>
<li><strong>Nvidia:</strong> High momentum and continued narrative as global market cap leader; rotate/focus on semis, AI-exposed stacks.</li>
<li><strong>Apple:</strong> Stagnant relative momentum (no new AI Siri at coming event); attention shifts to iPhone product cycle with expected higher pricing.</li>
<li><strong>Amazon:</strong> Stability at CEO level, though no near-term projection for global market cap dominance; operations unaffected by recent news.</li>
<li><strong>SpaceX:</strong> Record launch cadence and successful Starship launches underline defense/commercial/telecom supply chain dominance.</li>
<li><strong>Hyundai:</strong> Facing supply chain and diplomatic headwinds due to US immigration enforcement at its Georgia EV plant; closely watch for escalation affecting Korean/American industrial and trade equities.</li>
</ul>
<hr />
<h2>Summary Guideline</h2>
<ul>
<li><strong>Base Case:</strong> Expect moderate Fed easing, contained US recession risk, and policy/fiscal noise to be dominant volatility drivers.</li>
<li><strong>Overweights:</strong> Semiconductors, AI platforms/infrastructure, obesity/diabetes drug makers, and select defense/aerospace.</li>
<li><strong>Underweights/Caution:</strong> Firms reliant on US government contracts (shutdown risk), Korean/Japanese supply chain equities (US-Asia disputes), non-core EU sovereigns (political volatility).</li>
<li><strong>Monitor:</strong> Gaza/MENA escalation, US fiscal/political brinkmanship, South Korea-US industrial/trade relations, OpenAI governance, and Apple product pricing spin sometime post-Sept 9.</li>
</ul>

</main>
</body>
</html>
